Johnson & Johnson (JNJ)vsCharming Medical Limited Class A Ordinary Shares (MCTA)
JNJ
Johnson & Johnson
$275.19
+1.53%
HEALTHCARE · Cap: $615.87B
MCTA
Charming Medical Limited Class A Ordinary Shares
$29.36
0.00%
HEALTHCARE · Cap: $445.55M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 2066065% more annual revenue ($99.33B vs $4.81M). JNJ leads profitability with a 16.2% profit margin vs -0.5%. JNJ trades at a lower P/E of 38.8x. JNJ earns a higher WallStSmart Score of 57/100 (C).
JNJ
Buy57
out of 100
Grade: C
MCTA
Avoid11
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-83.0%
Fair Value
$144.12
Current Price
$275.19
$131.07 premium
Intrinsic value data unavailable for MCTA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 25.1%
Generating 6.4B in free cash flow
No standout strengths identified
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 96.0%
Distress zone — elevated risk
Smaller company, higher risk/reward
Operating margin of 4.9%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.1%.
Bull Case : MCTA
MCTA has a balanced fundamental profile.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Bear Case : MCTA
The primary concerns for MCTA are Altman Z-Score, Market Cap, Operating Margin. A P/E of 419.4x leaves little room for execution misses.
Key Dynamics to Monitor
JNJ profiles as a mature stock while MCTA is a turnaround play — different risk/reward profiles.
JNJ is growing revenue faster at 5.9% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
JNJ scores higher overall (57/100 vs 11/100), backed by strong 16.2% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Charming Medical Limited Class A Ordinary Shares
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Charming Medical Limited, engage in the provision of beauty, wellness, and postpartum services under the Beauty Lab brand name in Hong Kong. The company is headquartered in Causeway Bay, Hong Kong.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?